Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.
Research Center of Clinical Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.
Int J Mol Sci. 2020 Feb 3;21(3):1009. doi: 10.3390/ijms21031009.
Acute kidney injury (AKI) causes over 1 million deaths worldwide every year. AKI is now recognized as a major risk factor in the development and progression of chronic kidney disease (CKD). Diabetes is the main cause of CKD as well. Renal fibrosis and inflammation are hallmarks in kidney diseases. Various cytokines contribute to the progression of renal diseases; thus, many drugs that specifically block cytokine function are designed for disease amelioration. Numerous studies showed IL-20 functions as a pro-inflammatory mediator to regulate cytokine expression in several inflammation-mediated diseases. In this review, we will outline the effects of pro-inflammatory cytokines in the pathogenesis of AKI and CKD. We also discuss the role of IL-20 in kidney diseases and provide a potential therapeutic approach of IL-20 blockade for treating renal diseases.
急性肾损伤 (AKI) 每年在全球导致超过 100 万人死亡。AKI 现在被认为是慢性肾脏病 (CKD) 发展和进展的主要危险因素。糖尿病也是 CKD 的主要病因。肾脏纤维化和炎症是肾脏疾病的标志。各种细胞因子有助于肾脏疾病的进展；因此，许多专门阻断细胞因子功能的药物被设计用于改善疾病。许多研究表明，IL-20 作为一种促炎介质，可调节几种炎症介导的疾病中的细胞因子表达。在这篇综述中，我们将概述促炎细胞因子在 AKI 和 CKD 发病机制中的作用。我们还讨论了 IL-20 在肾脏疾病中的作用，并提供了一种通过阻断 IL-20 来治疗肾脏疾病的潜在治疗方法。
